
Pfizer Inc. announced Tuesday that it has launched a Phase 2/3 clinical trial of its COVID antiviral pill known as Paxlovid in children ages 6-17. A news release from the company said the trial will assess the safety and efficacy of the drug in children with COVID symptoms and a confirmed infection who are not… read on > read on >